Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Traws Pharma, Inc. Director's Dealing 2023

Jun 13, 2023

35199_dirs_2023-06-13_6fbc648a-a1d7-4a76-b63d-2941a284585e.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Onconova Therapeutics, Inc. (ONTX)
CIK: 0001130598
Period of Report: 2023-06-12

Reporting Person: Guerin Mark Patrick (N/A)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2023-06-12 Common Stock M 5500 Acquired 23691 Direct
2023-06-12 Common Stock F 1575 $1.137 Disposed 22116 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2023-06-12 Restricted Stock Units $ M 5500 Disposed Common Stock (5500) Direct

Footnotes

F1: Restricted stock units convert into common stock on a one-for-one basis.

F2: On June 10, 2022 the reporting person was granted 16,500 restricted stock units which vest over 3 years from the date of grant: 33% on the first anniversary; 33% on the second anniversary; and 34% on the third anniversary.